A. Oliver Sartor

A. Oliver Sartor, MD is among the world's foremost authorities on radiopharmaceutical therapy and bone-targeted treatment of advanced prostate cancer, having spent most of his career as Medical Director of Tulane Cancer Center before joining Novartis Institutes for BioMedical Research. Dr. Sartor is most widely known as the global principal investigator of the landmark ALSYMPCA trial (NEJM 2013), a phase III study of 921 mCRPC patients with symptomatic bone metastases and no known visceral metastases randomized to radium-223 dichloride or placebo. ALSYMPCA demonstrated a significant OS benefit (HR 0.70; p<0.001), reduced time to first SRE, and improved quality of life — the first alpha-particle emitter and the first radiopharmaceutical to improve overall survival in any solid tumor, earning FDA approval of radium-223 (Xofigo) in 2013. Dr. Sartor subsequently became deeply involved in the clinical development of 177Lu-PSMA-617, contributing to VISION trial design, patient accrual, and translational analyses, and is a leading voice on the theranostic paradigm for mCRPC. He has also made foundational contributions to the use of zoledronic acid for SRE prevention, samarium-153-EDTMP for bone pain palliation, and the preclinical and clinical biology of prostate cancer bone disease. Dr. Sartor has authored over 400 peer-reviewed publications and is a frequent keynote speaker at ASCO, APCCC, and EAU on radiopharmaceutical oncology and prostate cancer management.